Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG

Blood

Volumn 116, Issue 24, 2010, Pages 5327-5333

  Van Der Poel, Cees E ^a   Karssemeijer, Roos A ^a   Boross, Peter ^a   Van Der Linden, Joke A ^a   Blokland, Miranda ^a   Van De Winkel, Jan G J ^b   Leusen, Jeanette H W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC GAMMA R 1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; ERYTHROCYTE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 78650043719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-280214     Document Type: Article

References (41)

1. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725.
2. Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166(1):531-537. (Pubitemid 32038473)
3. Tridandapani S, Wardrop R, Baran CP, et al. TGF-β 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J Immunol. 2003;170(9):4572-4577.
4. Boruchov AM, Heller G, Veri MC, et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005;115(10):2914-2923.
5. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
6. Barnes N, Gavin AL, Tan PS, et al. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 2002;16(3):379-389.
7. Baudino L, Nimmerjahn F, Azeredo da Silveira S, et al. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol. 2008;180(3):1948-1953.
8. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 2002;16(3):391-402.
9. Bevaart L, Jansen MJ, van Vugt MJ, et al. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 2006;66(3):1261-1264. (Pubitemid 43259901)
10. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213.
11. McIntosh RS, Shi J, Jennings RM, et al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog. 2007;3(5):e72.
12. Dai X, Jayapal M, Tay HK, et al. Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa. Blood. 2009;114(2):318-327.
13. Keler T, Guyre PM, Vitale LA, et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol. 2000;165(12):6738-6742.
14. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.
15. Liu C, Goldstein J, Graziano RF, et al. F(c) gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J Clin Invest. 1996;98(9):2001-2007. (Pubitemid 26376287)
16. Heijnen IA, van Vugt MJ, Fanger NA, et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest. 1996;97(2):331-338.
17. Bakema JE, Bakker A, de Haij S, et al. Inside-out regulation of Fc alpha RI (CD89) depends on PP2A. J Immunol. 2008;181(6):4080-4088.
18. Bracke M, Nijhuis E, Lammers JW, Coffer PJ, Koenderman L. A critical role for PI 3-kinase in cytokine-induced Fcalpha-receptor activation. Blood. 2000;95(6):2037-2043.
19. Kanters D, ten Hove W, Luijk B, et al. Expression of activated Fc gamma RII discriminates between multiple granulocyte-priming phenotypes in peripheral blood of allergic asthmatic subjects. J Allergy Clin Immunol. 2007;120(5):1073-1081. (Pubitemid 350029883)
20. Koenderman L, Hermans SW, Capel PJ, van de Winkel JG. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. Blood. 1993;81(9):2413-2419.
21. Banno A, Ginsberg MH. Integrin activation. Biochem Soc Trans. 2008;36(Pt 2):229-234.
22. Beekman JM, Bakema JE, van de Winkel JG, Leusen JH. Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proc Natl Acad Sci U S A. 2004;101(28):10392-10397.
23. Miller KL, Duchemin AM, Anderson CL. A novel role for the Fc receptor gamma subunit: enhancement of Fc gamma R ligand affinity. J Exp Med. 1996;183(5):2227-2233.
24. Boot JH, Geerts ME, Aarden LA. Functional polymorphisms of Fc receptors in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. J Immunol. 1989;142(4):1217-1223.
25. Beekman JM, van der Poel CE, van der Linden JA, et al. FilaminAstabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol. 2008;180(6):3938-3945.
26. Beekman JM, Bakema JE, van der LJ, et al. Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. J Biol Chem. 2004;279(32):33875-33881.
27. Symons DB, Clarkson CA. Genomic organisation and sequence of the extracellular domain exons of the bovine Fc gamma RI receptor, and evidence for restricted binding of ruminant IgG to U937 cells. Mol Immunol. 1992;29(11):1407-1413.
28. Bracke M, Lammers JW, Coffer PJ, Koenderman L. Cytokine-induced inside-out activation of FcalphaR (CD89) is mediated by a single serine residue (S263) in the intracellular domain of the receptor. Blood. 2001;97(11):3478- 3483.
29. Ho AS, Wei SH, Mui AL, Miyajima A, Moore KW. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol Cell Biol. 1995;15(9):5043-5053.
30. Kumpel BM, Hadley AG. Functional interactions of red cells sensitized by IgG1 and IgG3 human monoclonal anti-D with enzyme-modified human monocytes and FcR-bearing cell lines. Mol Immunol. 1990;27(3):247-256. (Pubitemid 20111695)
31. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135-143.
32. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269(7):5241-5248.
33. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273(29):18623-18632.
34. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J. 1988;256(1):283-290.
35. Harrison PT, Allen JM. High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. Protein Eng. 1998;11(3):225-232.
36. Beekman JM, van der Linden JA, van de Winkel JG, Leusen JH. FcgammaRI (CD64) resides constitutively in lipid rafts. Immunol Lett. 2008;116(2):149-155.
37. Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol. 2009;182(12):8026-8036.
38. Dale BM, Traum D, Erdjument-Bromage H, Tempst P, Greenberg S. Phagocytosis in macrophages lacking Cbl reveals an unsuspected role for Fc gamma receptor signaling and actin assembly in target binding. J Immunol. 2009;182(9):5654-5662.
39. Jung ST, Reddy ST, Kang TH, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A. 2010;107(2):604-609.
40. Biglari A, Southgate TD, Fairbairn LJ, Gilham DE. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. Gene Ther. 2006;13(7):602-610.
41. Bevaart L, Goldstein J, Vitale L, et al. Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity. Br J Haematol. 2006;132(3):317-325.